Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469805 | 0.81 | FLT3 (0.71) | FLT3PDPK1 | |
| SCHEMBL19006335 | 0.77 | FLT3 (0.46) | FLT3 | |
| SCHEMBL17469737 | 0.74 | FLT3 (0.46) | FLT3PDPK1 | |
| SCHEMBL17469783 | 0.68 | FLT3 (0.52) | FLT3 | |
| SCHEMBL17469773 | 0.68 | FLT3 (0.52) | FLT3 | |
| SCHEMBL17459806 | 0.65 | FLT3 (0.47) | FLT3EGFRKDR | |
| SCHEMBL7258784 | 0.65 | FLT3 (0.45) | FLT3DHFR | |
| SCHEMBL19006228 | 0.64 | PLAU (0.40) | KDR | |
| SCHEMBL21103785 | 0.63 | FLT3 (0.76) | FLT3 | |
| SCHEMBL21103118 | 0.63 | FLT3 (0.76) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174620-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | FLT3 2354/4885PDPK1 2781/4885EGFR 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.